Agenus Stock Price, News & Analysis

Agenus Inc. (NASDAQ: AGEN) presented seven novel clinical programs at the SITC 2020 Annual Meeting. Key highlights include AGEN1181, showing clinical responses in hard-to-treat tumors and the first report of intratumoral Treg depletion. AGEN1777 offers improved immune performance as an Fc-enhanced TIGIT antibody. AGEN2373 demonstrates clinical benefit without liver toxicity. The proprietary VISION platform predicts treatment responses with high accuracy. Overall, these findings support Agenus's commitment to advancing immuno-oncology therapies.

Agenus Inc. has appointed Dr. Steven O'Day as its new Chief Medical Officer, enhancing its leadership as the company advances its pipeline of immuno-oncology therapies. Dr. O'Day brings over 30 years of experience and has been pivotal in the development of checkpoint antibody treatments. His expertise will support Agenus in rapidly developing clinical trials for their lead candidates. Dr. O'Day is set to present data on AGEN1181, a next-generation anti-CTLA-4 molecule, at an upcoming conference. This strategic appointment aims to accelerate innovative cancer treatments.

Agenus Inc. (NASDAQ: AGEN) has initiated the dosing of its first patient with agenT-797, an allogeneic iNKT cell therapy targeting moderate to severe COVID-19. This innovative therapy aims to eliminate the SARS-CoV-2 virus while curbing excessive inflammation. Additionally, the FDA has approved agenT-797 for cancer treatment, and trials for cancer patients are expected to begin soon. Agenus emphasizes its unique combination of therapies and cost-effectiveness in addressing critical health issues.

Agenus Inc. (NASDAQ: AGEN) provided a corporate update alongside its Q3 2020 financial results. The company initiated its rolling BLA filing for Balstilimab, with FDA review in progress. Recent clinical trials show Balstilimab achieving a 19% response rate in PD-L1 positive tumors and a combination with zalifrelimab yielding 27%. The cash balance rose to $114 million, while Q3 net loss was $52 million, a slight increase from $46 million in Q3 2019. Revenues totaled $14.8 million, down from $19.9 million in the prior year. New data on AGEN1181 will be presented at the upcoming SITC meeting.

Agenus Inc. (NASDAQ: AGEN) will announce its Q3 2020 financial results before the market opens on October 29, 2020. A conference call and webcast will follow at 8:30 AM ET for a discussion of the results and corporate update. Agenus specializes in immuno-oncology with an extensive pipeline including checkpoint antibodies, cell therapies, and vaccines aimed at enhancing immune responses to cancer and infections. The call will be accessible via the company’s website.

Agenus Inc. (NASDAQ: AGEN) announced the acceptance of seven abstracts for the virtual SITC 2020 Annual Meeting, scheduled for November 9-14, 2020. Key presentations include:

• AGEN1181: Demonstrates clinical activity as a standalone or in combination with balstilimab.
• Zalifrelimab: Shows clinical benefit in rare tumors.
• AGEN2373: A CD137 agonist antibody targeting antitumor effects.
• AgenT-797: A novel cell therapy promoting tumor killing.

Updated data will be available on the Agenus website post-conference.

Agenus Inc. (NASDAQ: AGEN) announced the election of Susan Hirsch to its Board of Directors, a significant move as the company prepares for its initial commercial product launches. Garo Armen, Chairman and CEO, praised Hirsch's extensive experience, particularly in identifying high-value companies at critical growth stages. With over 40 years in investment management, including a leadership role at Nuveen, Hirsch's expertise is expected to enhance Agenus' strategic direction. The company is focused on developing therapies that engage the immune system to combat cancer.

Agenus Inc. (NASDAQ: AGEN) announced the initiation of the rolling submission of its Biologics License Application (BLA) for balstilimab, an anti-PD-1 antibody, to the FDA for treating recurrent/metastatic cervical cancer. Results from a significant phase 2 trial indicated response rates of 19% in PD-L1 positive patients and 14% overall. The rolling BLA submission allows for concurrent FDA review of each section as it is completed. The American Cancer Society reported around 14,000 new cervical cancer cases expected this year, highlighting the need for new therapies.

Agenus Inc. (NASDAQ: AGEN) reported preliminary results from two Phase 2 clinical trials at the ESMO Virtual Congress 2020, focusing on recurrent/metastatic cervical cancer. The balstilimab monotherapy trial showed a 14% response rate overall and 19% in PD-L1 positive patients. The combination of balstilimab and zalifrelimab achieved a 22% overall response rate and 27% in PD-L1 positive patients. Notably, the median duration of response was 15.4 months for balstilimab alone. Both therapies show potential as new options for patients with limited treatment choices.